

Diabetes

1. El-Badawy A, El-Badri N. Clinical Efficacy of Stem Cell Therapy for Diabetes Mellitus: A Meta-Analysis. PLoS One. 2016 Apr 13;11(4):e0151938. doi: 10.1371/journal.pone.0151938. PubMed PmiD: 27073927; PubMed Central PMCID: PMC4830527.
2. Ranjbaran H, Mohammadi Jobani B, Amirfakhrian E, Alizadeh-Navaei R. Efficacy of mesenchymal stem cell therapy on glucose levels in type 2 diabetes mellitus: A systematic review and meta-analysis. J Diabetes Investig. 2021 May;12(5):803-810. doi: 10.1111/jdi.13404. Epub 2020 Oct 22. PmiD: 32926576; PMCID: PMC8089007.
3. Zhang Y, Chen W, Feng B, Cao H. The Clinical Efficacy and Safety of Stem Cell Therapy for Diabetes Mellitus: A Systematic Review and Meta-Analysis. Aging Dis. 2020 Feb 1;11(1):141-153. doi: 10.14336/AD.2019.0421. PmiD: 32010488; PMCID: PMC6961772.
4. He J, Kong D, Yang Z, Guo R, Amponsah AE, Feng B, Zhang X, Zhang W, Liu A, Ma J, O'Brien T, Cui H. Clinical efficacy on glycemic control and safety of mesenchymal stem cells in patients with diabetes mellitus: Systematic review and meta-analysis of RCT data. PLoS One. 2021 Mar 11;16(3):e0247662. doi: 10.1371/journal.pone.0247662. PmiD: 33705413; PMCID: PMC7951834.
5. Wu Q, Zheng S, Qin Y, Zheng X, Chen H, Yang T, Zhang M. Efficacy and safety of stem cells transplantation in patients with type 1 diabetes mellitus-a systematic review and meta-analysis. Endocr J. 2020 Aug 28;67(8):827-840. doi: 10.1507/endocrj.EJ20-0050. Epub 2020 May 23. PmiD: 32321876.
6. Madani S, Amanzadi M, Aghayan HR, Setudeh A, Rezaei N, Rouhifard M, Larijani B. Investigating the safety and efficacy of hematopoietic and mesenchymal stem cell transplantation for treatment of T1DM: a systematic review and meta-analysis. Syst Rev. 2022 May 2;11(1):82. doi: 10.1186/s13643-022-01950-3. PmiD: 35501872; PMCID: PMC9059401.
7. Rahim F, Arjmand B, Shirbandi K, Payab M, Larijani B. Stem cell therapy for patients with diabetes: a systematic review and meta-analysis of metabolomics-based risks and benefits. Non-coding RNA Investigation [Internet]. 2018 Nov [cited 2022 Sep 23];2:40.
8. Gan J, Wang Y, Zhou X. Stem cell transplantation for the treatment of patients with type 1 diabetes mellitus: A meta-analysis. Experimental and Therapeutic Medicine [Internet]. 2018 Sep 19.
9. <https://www.ncbi.nlm.nih.gov/pubmed/28006991> Bhansali S, Dutta P, Kumar V, Yadav MK, Jain A, Mudaliar S, et al. Efficacy of Autologous Bone Marrow-Derived Mesenchymal Stem Cell and

Mononuclear Cell Transplantation in Type 2 Diabetes Mellitus: A Randomized, Placebo-Controlled Comparative Study. *Stem Cells Dev.* 2017 01;26(7):471–81.

10. Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, et al. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. *Endocr J.* 2013;60(3):347–57.
11. Carlsson P-O, Schwarcz E, Korsgren O, Le Blanc K. Preserved β -cell function in type 1 diabetes by mesenchymal stromal cells. *Diabetes.* 2015 Feb;64(2):587–92.
12. Cai J, Wu Z, Xu X, Liao L, Chen J, Huang L, et al. Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion. *Diabetes Care.* 2016 Jan;39(1):149–57.
13. Skyler JS, Fonseca VA, Segal KR, Rosenstock J; MSB-DM003 Investigators. Allogeneic Mesenchymal Precursor Cells in Type 2 Diabetes: A Randomized, Placebo-Controlled, Dose-Escalation Safety and Tolerability Pilot Study. *Diabetes Care.* 2015 Sep;38(9):1742-9. doi: 10.2337/dc14-2830. Epub 2015 Jul 7. PubMed PmiD: 26153271; PubMed Central PMCID: PMC4542273.
14. Bhansali A, Asokumar P, Walia R, Bhansali S, Gupta V, Jain A, et al. Efficacy and safety of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus: a randomized placebo-controlled study. *Cell Transplant.* 2014;23(9):1075–85.
15. Packham DK, Fraser IR, Kerr PG, Segal KR. Allogeneic Mesenchymal Precursor Cells (MPC) in Diabetic Nephropathy: A Randomized, Placebo-controlled, Dose Escalation Study. *EBioMedicine.* 2016 Sep 17;12:263–9.
16. Haller MJ, Wasserfall CH, Hulme MA, Cintron M, Brusko TM, McGrail KM, Wingard JR, Theriaque DW, Shuster JJ, Ferguson RJ, Kozuch M, Clare-Salzler M, Atkinson MA, Schatz DA. Autologous umbilical cord blood infusion followed by oral docosahexaenoic acid and vitamin D supplementation for C-peptide preservation in children with Type 1 diabetes. *Biol Blood Marrow Transplant.* 2013 Jul;19(7):1126-9. doi: 10.1016/j.bbmt.2013.04.011. Epub 2013 Apr 20. PubMed PmiD: 23611977; PubMed Central PMCID: PMC3852705.
17. Wu Z, Cai J, Chen J, Huang L, Wu W, Luo F, et al. Autologous bone marrow mononuclear cell infusion and hyperbaric oxygen therapy in type 2 diabetes mellitus: an open-label, randomized controlled clinical trial. *Cytotherapy.* 2014 Feb;16(2):258–65.

18. Estrada EJ, Decima JL, Bortman G, Roberti J, Romero EB, Samaja G, Saavedra AR, Martínez G, Gutiérrez S. Combination treatment of autologous bone marrow stem cell transplantation and hyperbaric oxygen therapy for type 2 diabetes mellitus: A randomized controlled trial. *Cell Transplant*. 2019 Dec;28(12):1632-1640. doi: 10.1177/0963689719883813. Epub 2019 Oct 30. PmiD: 31665912; PMCID: PMC6923554.
19. Izadi M, Sadr Hashemi Nejad A, Moazenchi M, Masoumi S, Rabbani A, Kompani F, Hedayati Asl AA, Abbasi Kakroodi F, Jaroughi N, MohseniMeybodi MA, Setoodeh A, Abbasi F, Hosseini SE, Moeini Nia F, Salman Yazdi R, Navabi R, Hajizadeh-Saffar E, Baharvand H. Mesenchymal stem cell transplantation in newly diagnosed type-1 diabetes patients: a phase I/II randomized placebo-controlled clinical trial. *Stem Cell Res Ther*. 2022 Jun 20;13(1):264. doi: 10.1186/s13287-022-02941-w. PmiD: 35725652; PMCID: PMC9208234.
20. Zang L, Li Y, Hao H, Liu J, Cheng Y, Li B, Yin Y, Zhang Q, Gao F, Wang H, Gu S, Li J, Lin F, Zhu Y, Tian G, Chen Y, Gu W, Du J, Chen K, Guo Q, Yang G, Pei Y, Yan W, Wang X, Meng J, Zhang S, Ba J, Lyu Z, Dou J, Han W, Mu Y. Efficacy and safety of umbilical cord-derived mesenchymal stem cells in Chinese adults with type 2 diabetes: a single-center, double-blinded, randomized, placebo-controlled phase II trial. *Stem Cell Res Ther*. 2022 May 3;13(1):180. doi: 10.1186/s13287-022-02848-6. PmiD: 35505375; PMCID: PMC9066971.
21. Nguyen LT, Hoang DM, Nguyen KT, Bui DM, Nguyen HT, Le HTA, Hoang VT, Bui HTH, Dam PTM, Hoang XTA, Ngo ATL, Le HM, Phung NY, Vu DM, Duong TT, Nguyen TD, Ha LT, Bui HTP, Nguyen HK, Heke M, Bui AV. Type 2 diabetes mellitus duration and obesity alter the efficacy of autologously transplanted bone marrow-derived mesenchymal stem/stromal cells. *Stem Cells Transl Med*. 2021 Sep;10(9):1266-1278. doi: 10.1002/sctm.20-0506. Epub 2021 Jun 3. PmiD: 34080789; PMCID: PMC8380443.
22. Wu Z, Xu X, Cai J, Chen J, Huang L, Wu W, Pugliese A, Li S, Ricordi C, Tan J. Prevention of chronic diabetic complications in type 1 diabetes by co-transplantation of umbilical cord mesenchymal stromal cells and autologous bone marrow: a pilot randomized controlled open-label clinical study with 8-year follow-up. *Cytherapy*. 2022 Apr;24(4):421-427. doi: 10.1016/j.jcyt.2021.09.015. Epub 2022 Jan 25. PmiD: 35086778.
23. Li Y, Wang F, Liang H, Tang D, Huang M, Zhao J, Yang X, Liu Y, Shu L, Wang J, He Z, Liu Y. Efficacy of mesenchymal stem cell transplantation therapy for type 1 and type 2 diabetes mellitus:

- a meta-analysis. *Stem Cell Res Ther.* 2021 May 6;12(1):273. doi: 10.1186/s13287-021-02342-5. PmiD: 33957998; PMCID: PMC8101194.
24. Sun SY, Gao Y, Liu GJ, Li YK, Gao W, Ran XW. Efficacy and Safety of Stem Cell Therapy for T1DM: An Updated Systematic Review and Meta-Analysis. *J Diabetes Res.* 2020 Oct 10;2020:5740923. doi: 10.1155/2020/5740923. PmiD: 33102605; PMCID: PMC7569432.
25. Ye L, Li L, Wan B, Yang M, Hong J, Gu W, Wang W, Ning G. Immune response after autologous hematopoietic stem cell transplantation in type 1 diabetes mellitus. *Stem Cell Res Ther.* 2017 Apr 18;8(1):90. doi: 10.1186/s13287-017-0542-1. PubMed PmiD: 28420440; PubMed Central PMCID: PMC5395765.
26. Thakkar UG, Trivedi HL, Vanikar AV, Dave SD. Insulin-secreting adipose-derived mesenchymal stromal cells with bone marrow-derived hematopoietic stem cells from autologous and allogenic sources for type 1 diabetes mellitus. *Cytotherapy.* 2015 Jul;17(7):940–7.
27. Liu X, Zheng P, Wang X, Dai G, Cheng H, Zhang Z, Hua R, Niu X, Shi J, An Y. A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus. *Stem Cell Res Ther.* 2014 Apr 23;5(2):57. doi: 10.1186/scrt446. PubMed PmiD: 24759263; PubMed Central PMCID: PMC4055092.
28. D'Addio F, Valderrama Vasquez A, Ben Nasr M, Franek E, Zhu D, Li L, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in new-onset type 1 diabetes: a multicenter analysis. *Diabetes.* 2014 Sep;63(9):3041–6.
29. Gu B, miao H, Zhang J, Hu J, Zhou W, Gu W, et al. Clinical benefits of autologous haematopoietic stem cell transplantation in type 1 diabetes patients. *Diabetes Metab.* 2018 Sep;44(4):341–5.
30. Voltarelli JC, Couri CEB, Stracieri ABPL, Oliveira MC, Moraes DA, Pieroni F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. *JAMA.* 2007 Apr 11;297(14):1568–76.
31. Zhao Y, Jiang Z, Zhao T, Ye M, Hu C, Zhou H, Yin Z, Chen Y, Zhang Y, Wang S, Shen J, Thaker H, Jain S, Li Y, Diao Y, Chen Y, Sun X, Fisk MB, Li H. Targeting insulin resistance in type 2 diabetes via immune modulation of cord blood-derived multipotent stem cells (CB-SCs) in stem cell educator therapy: phase I/II clinical trial. *BMC Med.* 2013 Jul 9;11:160. doi: 10.1186/1741-7015-11-160. PubMed PmiD: 23837842; PubMed Central PMCID: PMC3716981.

32. Gu W, Hu J, Wang W, Li L, Tang W, Sun S, et al. Diabetic Ketoacidosis at Diagnosis Influences Complete Remission After Treatment With Hematopoietic Stem Cell Transplantation in Adolescents With Type 1 Diabetes. *Diabetes Care*. 2012 Jul;35(7):1413–9.
33. Couri CEB, Oliveira MCB, Stracieri ABPL, Moraes DA, Pieroni F, Barros GMN, et al. C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. *JAMA*. 2009 Apr 15;301(15):1573–9.
34. Li L, Shen S, Ouyang J, Hu Y, Hu L, Cui W, et al. Autologous hematopoietic stem cell transplantation modulates immunocompetent cells and improves β -cell function in Chinese patients with new onset of type 1 diabetes. *J Clin Endocrinol Metab*. 2012 May;97(5):1729–36.
35. Vanikar AV, Dave SD, Thakkar UG, Trivedi HL. Cotransplantation of Adipose Tissue-Derived Insulin-Secreting Mesenchymal Stem Cells and Hematopoietic Stem Cells: A Novel Therapy for Insulin-Dependent Diabetes Mellitus. *Stem Cells Int* [Internet]. 2010 Dec 20 [cited 2019 Apr 30];2010. Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3010655/>
36. Araujo DB, Dantas JR, Silva KR, Souto DL, Pereira MFC, Moreira JP, Luiz RR, Claudio-Da-Silva CS, Gabbay MAL, Dib SA, Couri CEB, Maiolino A, Rebelatto CLK, Daga DR, Senegaglia AC, Brofman PRS, Baptista LS, Oliveira JEP, Zajdenverg L, Rodacki M. Allogenic Adipose Tissue-Derived Stromal/Stem Cells and Vitamin D Supplementation in Patients With Recent-Onset Type 1 Diabetes Mellitus: A 3-Month Follow-Up Pilot Study. *Front Immunol*. 2020 Jun 2;11:993. doi: 10.3389/fimmu.2020.00993. PmiD: 32582156; PMCID: PMC7280537.
37. Lu J, Shen SM, Ling Q, Wang B, Li LR, Zhang W, Qu DD, Bi Y, Zhu DL. One repeated transplantation of allogeneic umbilical cord mesenchymal stromal cells in type 1 diabetes: an open parallel controlled clinical study. *Stem Cell Res Ther*. 2021 Jun 10;12(1):340. doi: 10.1186/s13287-021-02417-3. PmiD: 34112266; PMCID: PMC8194026.
38. Hu J, Li C, Wang L, Zhang X, Zhang M, Gao H, et al. Long term effects of the implantation of autologous bone marrow mononuclear cells for type 2 diabetes mellitus. *Endocr J*. 2012;59(11):1031–9.
39. Kassem DH, Kamal MM. Therapeutic efficacy of umbilical cord-derived stem cells for diabetes mellitus: a meta-analysis study. *Stem Cell Res Ther*. 2020 Nov 16;11(1):484. doi: 10.1186/s13287-020-01996-x. PmiD: 33198815; PMCID: PMC7667841.

40. Giannopoulou EZ, Puff R, Beyerlein A, von Luettichau I, Boerschmann H, Schatz D, et al. Effect of a single autologous cord blood infusion on beta-cell and immune function in children with new onset type 1 diabetes: a non-randomized, controlled trial. *Pediatr Diabetes*. 2014 Mar;15(2):100–9.
41. Snarski E, milczarczyk A, Hałaburda K, Torosian T, Paluszewska M, Urbanowska E, et al. Immunoablation and autologous hematopoietic stem cell transplantation in the treatment of new-onset type 1 diabetes mellitus: long-term observations. *Bone Marrow Transplant*. 2016 Mar;51(3):398–402.
42. Kong D, Zhuang X, Wang D, Qu H, Jiang Y, Li X, et al. Umbilical cord mesenchymal stem cell transfusion ameliorated hyperglycemia in patients with type 2 diabetes mellitus. *Clin Lab*. 2014;60(12):1969–76.
43. Bhansali A, Upreti V, Khandelwal N, Marwaha N, Gupta V, Sachdeva N, et al. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. *Stem Cells Dev*. 2009 Dec;18(10):1407–16.
44. Mesples A, Majeed N, Zhang Y, Hu X. Early immunotherapy using autologous adult stem cells reversed the effect of anti-pancreatic islets in recently diagnosed type 1 diabetes mellitus: Preliminary results. *Med Sci Monit*. 2013 Oct 14;19:852–7.
45. Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, et al. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. *Front Med*. 2011 Mar;5(1):94–100.
46. Estrada EJ, Valacchi F, Nicora E, Brieva S, Esteve C, Echevarria L, et al. Combined treatment of intrapancreatic autologous bone marrow stem cells and hyperbaric oxygen in type 2 diabetes mellitus. *Cell Transplant*. 2008;17(12):1295–304.
47. Snarski E, milczarczyk A, Torosian T, Paluszewska M, Urbanowska E, Król M, et al. Independence of exogenous insulin following immunoablation and stem cell reconstitution in newly diagnosed diabetes type I. *Bone Marrow Transplant*. 2011 Apr;46(4):562–6.
48. Al Demour S, Jafar H, Adwan S, AlSharif A, Alhawari H, Alrabadi A, et al. Safety and Potential Therapeutic Effect of Two Intracavernous Autologous Bone Marrow Derived Mesenchymal Stem Cells injections in Diabetic Patients with Erectile Dysfunction: An Open Label Phase I Clinical Trial. *Urol Int*. 2018;101(3):358–65.
49. Zhang X, Ye L, Hu J, Tang W, Liu R, Yang M, et al. Acute Response of Peripheral Blood Cell to Autologous Hematopoietic Stem Cell Transplantation in Type 1 Diabetic Patient. *PLoS One*

[Internet]. 2012 Feb 22 [cited 2019 Apr 30];7(2). Available from: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3285188/>

50. Trivedi HL, Vanikar AV, Thakker U, Firoze A, Dave SD, Patel CN, et al. Human adipose tissue-derived mesenchymal stem cells combined with hematopoietic stem cell transplantation synthesize insulin. *Transplant Proc.* 2008 May;40(4):1135–9.
51. Tong Q, Duan L, Xu Z, Wang H, Wang X, Li Z, et al. Improved insulin secretion following intrapancreatic UCB transplantation in patients with T2DM. *J Clin Endocrinol Metab.* 2013 Sep;98(9):E1501-1504.
52. Mohamed MT, Embaby EA, Labib A, El-Husseiny M, Khamis H, El-Demery A, Shoukry MM. Effects of exercise in combination with autologous bone marrow stem cell transplantation for patients with type 1 diabetes. *Physiother Theory Pract.* 2019 Dec;35(12):1233-1242. doi: 10.1080/09593985.2018.1474511. Epub 2018 May 18. PmiD: 29775119.
53. Dantas JR, Araújo DB, Silva KR, Souto DL, de Fátima Carvalho Pereira M, Luiz RR, Dos Santos Mantuano M, Claudio-da-Silva C, Gabbay MAL, Dib SA, Couri CEB, Maiolino A, Rebelatto CLK, Daga DR, Senegaglia AC, Brofman PRS, Baptista LS, de Oliveira JEP, Zajdenverg L, Rodacki M. Adipose tissue-derived stromal/stem cells + cholecalciferol: a pilot study in recent-onset type 1 diabetes patients. *Arch Endocrinol Metab.* 2021 Nov 3;65(3):342-351. doi: 10.20945/2359-3997000000368. Epub 2021 Apr 29. PmiD: 33939911.
54. Shroff, G. (2015) Use of Human Embryonic Stem Cells in the Treatment of Diabetes Mellitus: A Case Series. *Journal of Diabetes Mellitus*, 5, 313-318. doi: 10.4236/jdm.2015.54038.
55. Dave SD, Trivedi HL, Chooramani SG, Chandra T. Management of type 1 diabetes mellitus using in vitro autologous adipose tissue trans-differentiated insulin-making cells. *Case Reports.* 2013 Jul 26 ;2013(jul26 1):bcr2013200226. Available from: <https://doi.org/10.1136/bcr-2013-200226>
56. Liu Y, Cao DL, Guo LB, Guo SN, Xu JK, Zhuang HF. Amniotic stem cell transplantation therapy for type 1 diabetes: a case report. *Journal of international medical research.* 2013 Aug;41(4):1370-7.
57. Bahk JY, Jung JH, Han H, min SK, Lee YS. Treatment of diabetic impotence with umbilical cord blood stem cell intracavernosal transplant: preliminary report of 7 cases. *Exp Clin Transplant.* 2010 Jun 1;8(2):150-60.